UroGen Pharma (URGN) Short-term Investments (2016 - 2026)

UroGen Pharma (URGN) has reported Short-term Investments for 11 consecutive years, with $30.3 million the latest figure, recorded in Q1 2026.

• Quarterly Short-term Investments fell 67.01% year-over-year to $30.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.3 million (down 67.01% YoY) and the FY2025 annual result came in at $9.7 million, down 84.99% from the prior year.
• Short-term Investments improved to $30.3 million in Q1 2026 per URGN's latest filing, from $9.7 million in the prior quarter.
• Over the last five years, Short-term Investments for URGN reached as high as $124.7 million in Q3 2024 and fell as low as $9.7 million in Q4 2025.
• A 5-year average of $45.6 million and a median of $32.6 million in 2024 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2024 — Short-term Investments surged 343.41% — and 2025, when it slumped 84.99%.
• Year by year, Short-term Investments stood at $44.6 million in 2022, then fell by 5.81% to $42.0 million in 2023, then soared by 54.17% to $64.7 million in 2024, then sank by 84.99% to $9.7 million in 2025, then surged by 212.08% to $30.3 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $30.3 million, $9.7 million, and $37.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.